Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
|
|
ZEVRA THERAPEUTICS, INC. (KMPH)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/11/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/11/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 10/10/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 10/10/2023 |
8-K
| Quarterly results |
| 10/10/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 10/06/2023 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
| 09/28/2023 |
S-4
| Form S-4 - Registration of securities, business combinations: |
| 08/25/2023 |
4
| Anderson Thomas (Director) has filed a Form 4 on ZEVRA THERAPEUTICS, INC.|
Txns:
| Granted 58,800 options to buy
@ $0 |
|
| 08/24/2023 |
3
| Anderson Thomas (Director) has filed a Form 3 on ZEVRA THERAPEUTICS, INC. |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Investor presentation |
| 08/07/2023 |
8-K
| Appointed a new director |
| 06/30/2023 |
4
| Schafer Joshua (CCO & EVP, Bus. Development) has filed a Form 4 on ZEVRA THERAPEUTICS, INC.|
Txns:
| Bought 1,000 shares
@ $5.4157, valued at
$5.4k
|
|
| 06/02/2023 |
4
| FAVORITO TAMARA A (Director) has filed a Form 4 on ZEVRA THERAPEUTICS, INC.|
Txns:
| Granted 10,000 options to buy
@ $0 |
|
| 05/31/2023 |
4
| Watton Corey Michael (Director) has filed a Form 4 on ZEVRA THERAPEUTICS, INC.|
Txns:
| Bought 400 shares
@ $5.1053, valued at
$2k
|
|
| 05/19/2023 |
4
| Bode John B (Director) has filed a Form 4 on ZEVRA THERAPEUTICS, INC.|
Txns:
| Bought 1,390 shares
@ $5.035, valued at
$7k
Bought 300 shares
@ $5.0391, valued at
$1.5k
Bought 1,000 shares
@ $5.0399, valued at
$5k
Bought 4,759 shares
@ $5.04, valued at
$24k
Bought 100 shares
@ $5.045, valued at
$504.5
Bought 2,451 shares
@ $5.05, valued at
$12.4k
|
|
| 05/18/2023 |
4
| Clifton R. LaDuane (CFO, Secretary & Treasurer) has filed a Form 4 on ZEVRA THERAPEUTICS, INC.|
Txns:
| Bought 51 shares
@ $4.94, valued at
$251.9
Bought 2,000 shares
@ $4.9499, valued at
$9.9k
Bought 689 shares
@ $4.9495, valued at
$3.4k
|
|
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
4
| Calder Douglas W (Director) has filed a Form 4 on ZEVRA THERAPEUTICS, INC.|
Txns:
| Granted 58,800 options to buy
@ $0 |
|
| 05/11/2023 |
3
| Calder Douglas W (Director) has filed a Form 3 on ZEVRA THERAPEUTICS, INC. |
| 05/08/2023 |
4
| Watton Corey Michael (Director) has filed a Form 4 on ZEVRA THERAPEUTICS, INC.|
Txns:
| Granted 58,800 options to buy
@ $0 |
|
| 05/08/2023 |
4
| Saluri Joseph (Director) has filed a Form 4 on ZEVRA THERAPEUTICS, INC.|
Txns:
| Granted 39,200 options to buy
@ $0 |
|
| 05/08/2023 |
4
| Plooster Matthew R (Director) has filed a Form 4 on ZEVRA THERAPEUTICS, INC.|
Txns:
| Granted 49,200 options to buy
@ $0 |
|
| 05/08/2023 |
4
| FAVORITO TAMARA A (Director) has filed a Form 4 on ZEVRA THERAPEUTICS, INC.|
Txns:
| Granted 39,200 options to buy
@ $0 |
|
| 05/08/2023 |
4
| DIXON WENDY L (Director) has filed a Form 4 on ZEVRA THERAPEUTICS, INC.|
Txns:
| Granted 22,500 options to buy
@ $0
Granted 36,300 options to buy
@ $0 |
|
| 05/08/2023 |
4
| Bode John B (Director) has filed a Form 4 on ZEVRA THERAPEUTICS, INC.|
Txns:
| Granted 58,800 options to buy
@ $0 |
|
| 05/08/2023 |
3
| Watton Corey Michael (Director) has filed a Form 3 on ZEVRA THERAPEUTICS, INC. |
| 05/08/2023 |
3
| DIXON WENDY L (Director) has filed a Form 3 on ZEVRA THERAPEUTICS, INC. |
| 05/08/2023 |
3
| Bode John B (Director) has filed a Form 3 on ZEVRA THERAPEUTICS, INC. |
| 05/08/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 04/26/2023 |
8-K
| Quarterly results |
| 04/17/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/03/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/30/2023 |
8-K
| Quarterly results |
|
|
|